The effect of angiotensin receptors and neprilysin inhibitors on myocardial remodeling in patients with chronic heart failure and atrial fibrillation

Uskach, T. M.; Safiullina, A. A.; Makeev, M. I.; Саидова, М. А.; Shariya, M.A.; Ustyuzhanin, D.; Жиров, И. В.; Tereshchenko, S. N.

doi:10.18087/cardio.n815

Cited by 3 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, in the PIONEER-HF study in patients with HFrEF who were hospitalized for acute decompensated heart failure, the initiation of sacubitril-valsartan therapy led to a greater reduction in the NT-proBNP concentration than enalapril therapy ( 19 ). Another study noted that sacubitril/valsartan in patients with CHF and atrial fibrillation leads to a significant decrease in the level of brain natriuretic peptide and showed a clear trend towards reversing myocardial remodeling ( 21 ).…”

Section: Discussionmentioning

confidence: 99%

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling

Ryazanov

Ших

Makarovskaya³

et al. 2023

Braz J Med Biol Res

View full text Add to dashboard Cite

The aim of this study was to determine how sacubitril/valsartan compared with valsartan in an outpatient setting affects left ventricular remodeling in heart failure with reduced ejection fraction and functional (or secondary) mitral regurgitation (SMR) due to the effect of dual inhibition of the renin-angiotensin system and neprilysin. The outpatient study included 90 patients with chronic SMR who were followed up for 12 months. They received sacubitril/valsartan or valsartan instead of the more commonly used angiotensin-converting enzyme inhibitor enalapril for heart failure, in addition to standard medical therapy for heart failure. The difference in NT-proBNP change between groups was the primary endpoint. Changes in effective regurgitation orifice area, left ventricular ejection fraction, left ventricular end-systolic and end-diastolic volume indices, left atrial volume index, E/e' index, and exercise tolerance on the 6-minute walk test were secondary endpoints. In the treatment efficacy analysis, NT-proBNP levels decreased significantly by 37% in the sacubitril/valsartan group and by 11% in the valsartan group (P<0.001). Ejection fraction and exercise tolerance (increase in walking distance in the 6-min test) increased in the sacubitril/valsartan group (P<0.05). Also, in this group, the effective area of the regurgitation orifice, the left atrial volume index, the E/e' index, and the indices of the end-systolic and end-diastolic volume of the left ventricle (P<0.05) decreased more pronouncedly. Compared with valsartan, treatment with sacubitril/valsartan led to a significant improvement in cardiac remodeling in patients with SMR and heart failure with reduced ejection fraction.

show abstract

Section: Discussionmentioning

confidence: 99%

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling

Ryazanov

Ших

Makarovskaya³

et al. 2023

Braz J Med Biol Res

View full text Add to dashboard Cite

show abstract

“…It is important to note that the severity of pathologic MR has a great influence on the further development of CHF of ischemic etiology [6]. At the same time, there is convincing evidence that progressive MR can be not only stopped, but also reversed, which results in improvement of both the systole-diastolic function (in particular, the restoration of the LV ejection fraction (LVEF) and the clinical condition of patients with CHF [7][8][9]). Since this process is important in determining the prognosis, course, and quality of further life in patients with CHF and CHD, it is necessary to identify potential markers of MR that can open new or help rethink the existing approaches in medication.…”

Section: Introductionmentioning

confidence: 99%

Relationship of Acylcarnitines to Myocardial Ischemic Remodeling and Clinical Manifestations in Chronic Heart Failure

Belenkov,

Ageev,

Kozhevnikova

et al. 2023

JCDD

View full text Add to dashboard Cite

Background: Progressive myocardial remodeling (MR) in chronic heart failure (CHF) leads to aggravation of systolic dysfunction (SD) and clinical manifestations. Identification of metabolomic markers of these processes may help in the search for new therapeutic approaches aimed at achieving reversibility of MR and improving prognosis in patients with CHF. Methods: To determine the relationship between plasma acylcarnitine (ACs) levels, MR parameters and clinical characteristics, in patients with CHF of ischemic etiology (n = 79) and patients with coronary heart disease CHD (n = 19) targeted analysis of 30 ACs was performed by flow injection analysis mass spectrometry. Results: Significant differences between cohorts were found for the levels of 11 ACs. Significant positive correlations (r > 0.3) between the medium- and long-chain ACs (MCACs and LCACs) and symptoms (CHF NYHA functional class (FC); r = 0.31−0.39; p < 0.05); negative correlation (r = −0.31−0.34; p < 0.05) between C5-OH and FC was revealed. Positive correlations of MCACs and LCACs (r = 0.31−0.48; p < 0.05) with the left atrium size and volume, the right atrium volume, right ventricle, and the inferior vena cava sizes, as well as the pulmonary artery systolic pressure level were shown. A negative correlation between C18:1 and left ventricular ejection fraction (r = −0.31; p < 0.05) was found. However, a decrease in levels compared to referent values of ACs with medium and long chain lengths was 50% of the CHF-CHD cohort. Carnitine deficiency was found in 6% and acylcarnitine deficiency in 3% of all patients with chronic heart disease. Conclusions: ACs may be used in assessing the severity of the clinical manifestations and MR. ACs are an important locus to study in terms of altered metabolic pathways in patients with CHF of ischemic etiology and SD. Further larger prospective trials are warranted and needed to determine the potential benefits to treat patients with CV diseases with aberrate AC levels.

show abstract

Heart failure and atrial fibrillation: updates and perspectives

Ларина

Skiba

et al. 2022

Russ J Cardiol

View full text Add to dashboard Cite

The article discusses modern approaches and features of management, as well as predicting the risk of complications in patients with cardiac arrhythmias, in particular, atrial fibrillation, and the potential of using conservative and interventional treatment methods for heart failure (HF), taking into account updates and achievements in clinical practice. Epidemiological data, algorithms for managing patients with HF and atrial fibrillation, prevention of thromboembolic events, results of studies comparing the effectiveness of different strategies for atrial fibrillation treatment, catheter ablation compared with drug therapy in patients with HF are presented.

show abstract

The effect of angiotensin receptors and neprilysin inhibitors on myocardial remodeling in patients with chronic heart failure and atrial fibrillation

Cited by 3 publications

References 27 publications

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling

Angiotensin receptor-neprilysin inhibitors and cardiac remodeling

Relationship of Acylcarnitines to Myocardial Ischemic Remodeling and Clinical Manifestations in Chronic Heart Failure

Heart failure and atrial fibrillation: updates and perspectives

Contact Info

Product

Resources

About